Keyword: Farxiga

With outcomes data showing Farxiga lowers hospitalizations for heart failure or CV deaths against placebo, AZ plans to file for a new FDA label.

With data showing Farxiga can reduce hospitalizations for heart failure or CV deaths against placebo, AZ plans to seek a label update.

The FDA has raised red flags about a potentially serious flesh-eating disease in patients taking SGLT2 inhibitors.

J&J’s Invokana will have to wait longer for the FDA to decide on a key label expansion, but it's still got good news to celebrate.

At ADA, an AstraZeneca executive said he's "very optimistic" about the company's cardiovascular outcomes study for Farxiga.

In a new post-hoc analysis of Jardiance's CV outcomes test, investigators found that the drug reduced kidney disease progression.

Invokana carries a warning for amputation risks, but an analysis found the drug lowered heart failure hospitalizations without increasing those risks.

AstraZeneca may be the first pharma to encourage use of the “F-word.” Although in this case, AZ is talking about its diabetes drug Farxiga.

When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.

Lilly and BI are gunning for a heart-failure nod for Jardiance. And they want to be able to talk up the drug’s effects on exercise ability, too.